Combination therapy for fit (younger and older) newly diagnosed multiple myeloma patients: Data support carfilzomib, lenalidomide, and dexamethasone independent of cytogenetic risk status: Beyond the Abstract

In 2017, the standard of care for the treatment of a newly diagnosed patients with multiple myeloma is based on a 3-drug combination. Which are the optimal drugs to combine? What evidence is there to support various combinations? The current invited paper provides a critical review of available scientific literature, and it sheds light on the actual data behind established, well-respected expert guidelines.
Read more ...

Dibenzoyl-methane Derivatives as a Potential and Exciting New Therapy for the Treatment of Childhood Bone Cancer: Beyond the Abstract

Cancer in children and young adults is rare, with survival rates being very high, mainly depending on the treatment. The biggest proportion of these diagnosis will be on leukaemia and brain tumours, with just about 3% of them, related to bone cancer, mainly osteosarcoma and Erwing’s sarcoma [1]. Bone cancer affects children of growing age, if it has not spread from the tumour site, survival rate are around 60-80% [6] but this is highly affected by diagnosis stage (with early diagnosis being more favourable), tumour’s size and location.[10]
Read more ...

About thymic carcinomas: challenges in diagnosis and management: Beyond the Abstract

Thymic carcinomas (TC) are rare mediastinal tumors characterized by a challenging diagnosis and management [1,2]. These tumors are classified within thymic tumors according to the 2015 World Health Organization Classification. Clinical symptoms are non specific resulting in a delayed diagnosis [1]. Radiological findings are also non specific. In fact, they help to highlight the malignant nature of the tumor without presuming of its nature.
Read more ...

Patterns of Care and Survival for Elderly Acute Myeloid Leukemia - Challenges and Opportunities: Beyond the Abstract

Acute myeloid leukemia (AML) is a disease of the elderly, with median age of diagnosis in the sixties. The survival for this subset has largely remained unchanged despite improvements in their younger counterparts. Previous studies have highlighted several reasons for this trend.
Read more ...

Targeted Therapy has not Substantially Improved Outcomes in Patients with Sarcomatoid Renal Cell Carcinoma: Beyond the Abstract

Renal cell carcinomas (RCCs) of any histologic subtype can undergo sarcomatoid dedifferentiation which confers a poor prognosis. Over the past decade, targeted therapies against the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways have substantially improved outcomes in patients with advanced clear-cell RCC.1 To determine whether these benefits are also evident in RCCs with sarcomatoid dedifferentiation (sRCCs), we performed a retrospective analysis of our institutional experience with sRCCs, and explored whether the survival of these patients improved since the introduction of targeted therapies.2 
Read more ...

New Developments in Diagnosis, Prognosis, and Assessment of Response in Multiple Myeloma: Beyond the Abstract

Multiple myeloma has become a poster child of success in hematology-oncology. Driven by access to modern treatment, on average, patient survival is over 10 (-20) years in multiple myeloma patients treated in the U.S. Also diagnostics and prognostics, as well as assessment of treatment response have improved greatly.
Read more ...

Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in Chronic Lymphocytic Leukemia: Results from a Multi-Center Study of 683 Patients: Beyond the Abstract

Outcomes of Chronic Lymphocytic Leukemia (CLL) patients have significantly improved in the past decades. Patients are now expected to enjoy higher response rates, deeper remission, and longer survival. In addition, better understanding to the pathobiology of CLL has led to approving three oral drugs that exploit the mechanism of disease development and progression.
Read more ...
@OncToday